去纤苷多少钱一盒?在哪里购买?

Defitelio is a specific drug for the treatment of hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Its price information and purchase channels are crucial to patients. This article will introduce the price, purchase method and pharmacokinetic properties of this drug in detail to provide patients with a comprehensive medication reference.

How much does a box of defibrotide cost?

It is an orphan drug, and its pricing strategy is significantly different from that of ordinary drugs. Understanding its price structure can help patients plan their treatment budget.

International market price

The price of Defitelio produced by Irish Jazz Pharmaceuticals in the US market is approximately US$5,310 per box, and each box is 200mg/2.5mL. Prices in the European market are similar, with minor regional differences.

Estimation of cost of treatment course

The standard treatment plan usually requires continuous medication for 21 days, with a daily dose of 6.25mg/kg. Calculated based on a 60kg adult, the total treatment cost is approximately US$50,000 to US$80,000, depending on the patient's weight and duration of medication.

Factors affecting price

The high R&D costs of orphan drugs and the small number of applicable people are the main pricing factors. Patient assistance programs may be available in some areas and actual amount paid may be less than listed price.

Patients should consult medical institutions to obtain the latest price information and understand possible cost reduction policies before purchasing drugs.

Where to buy defibrotide

Due to the particularity of defibrotide, its purchasing channels are significantly different from conventional drugs.

Designated medical institutions

Most countries limit sales to hospitals with hematopoietic stem cell transplant qualifications. Patients must purchase them in hospital pharmacies with a prescription from a specialist. The storage and use of drugs require professional supervision.

Special import channels

In unlisted areas, hospitals can apply for import through the "compassionate use" procedure. This process requires complete medical records and the approval time is about 4-6 weeks.

Note on cross-border drug purchases

Individuals carrying cross-border drugs must comply with customs drug management regulations, provide a doctor's prescription and diagnosis certificate, and cold chain transportation conditions must meet the requirements.

When purchasing, you should check the integrity of drug packaging, confirm that the batch number is consistent with the instructions, and reject drugs from unknown sources.

Pharmacokinetics of defibrotide

Understanding the metabolic process of defibrotide in the body is of guiding significance for rational drug use. Its unique pharmacokinetic properties directly affect the design of dosing regimen.

Absorption and Distribution

The peak concentration is reached at the end of intravenous infusion, and the plasma protein binding rate is as high as 93%. It is widely distributed in vascular endothelium, with an apparent volume of distribution of 8.1-9.1L.

Metabolic pathway

It is mainly degraded into oligonucleotide fragments by nucleases, and the liver and kidneys are hardly involved in metabolism. This feature makes it unnecessary to adjust the dose in patients with organ dysfunction.

Excretion characteristics

The elimination half-life is shorter than 2 hours, and 5%-15% is excreted unchanged in the urine. It is not effectively removed by hemodialysis and does not require additional intervention in patients with renal insufficiency.

Clinical efficacy rather than blood drug concentration should be monitored during medication, and the infusion rate and treatment duration should be adjusted according to patient response.